PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer

KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC

Subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer

Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer

Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment

Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients

Comment: The success of immunotherapy means we have to change our mindset as we treat patients

Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers

Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy

Highlights from SIOP Africa 2019 (French)